DC
NKTR icon

Deere & Company’s Nektar Therapeutics NKTR Stock Holding History

Deere & Company’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,832
Closed -$463K – 1115
2015
Q4 		$463K Sell
1,832
-638
-26% -$131K 0.03% 589
2015
Q3 		$406K Sell
2,470
-459
-16% -$81.2K 0.03% 655
2015
Q2 		$550K Buy
2,929
+1,905
+186% +$328K 0.03% 606
2015
Q1 		$169K Hold
1,024
– – 0.01% 931
2014
Q4 		$238K Hold
1,024
– – 0.01% 805
2014
Q3 		$185K Buy
+1,024
New +$196K 0.01% 907
2014
Q2 		– Sell
-2,871
Closed -$522K – 1004
2014
Q1 		$522K Buy
+2,871
New +$568K 0.03% 626

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deere & Company's NKTR Position: Q1 2016 in Review

Deere & Company sold out of Nektar Therapeutics (NKTR) in Q1 2016, closing a stake of 1,832 shares — an estimated $463K sold.

Deere & Company first reported a position in NKTR in Q1 2014 and held it in 7 quarters. The position peaked at $550K in Q2 2015. 176 funds tracked by Wall St. Rank hold NKTR as of Q1 2016.

  • Deere & Company reported no remaining Nektar Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Deere & Company sold 1,832 Nektar Therapeutics shares in Q1 2016, an estimated $463K.
  • Deere & Company first reported a position in Nektar Therapeutics in Q1 2014 and held it in 7 quarters.
  • Deere & Company's Nektar Therapeutics position peaked at $550K in Q2 2015.
  • 176 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2016.

Based on Deere & Company's 13F filing for Q1 2016, filed 9 May 2016.